KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EBT: 2009-2024

Historic EBT for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to -$377.4 million.

  • Alnylam Pharmaceuticals' EBT rose 319.92% to $239.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.9 million, marking a year-over-year increase of 90.05%. This contributed to the annual value of -$377.4 million for FY2024, which is 12.95% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported EBT of -$377.4 million as of FY2024, which was up 12.95% from -$433.5 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' EBT ranged from a high of -$377.4 million in FY2024 and a low of -$1.1 billion during FY2022.
  • Over the past 3 years, Alnylam Pharmaceuticals' median EBT value was -$433.5 million (recorded in 2023), while the average stood at -$646.0 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' EBT slumped by 32.25% in 2022, and later skyrocketed by 61.53% in 2023.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' EBT stood at -$855.6 million in 2020, then grew by 0.40% to -$852.1 million in 2021, then plummeted by 32.25% to -$1.1 billion in 2022, then surged by 61.53% to -$433.5 million in 2023, then climbed by 12.95% to -$377.4 million in 2024.